Tiziana Life Sciences Ltd. (TLSA) Stock Price, Financials & Summary

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$1.06

From 52W high−48.47%

Volume331788.00

Market cap$128.53M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataOct 19, 2026

Open

$1.06

From 52W high

−48.47%

Volume

331788.00

Market cap

$128.53M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−5.4x

P/E (TTM)

—

RSI (14)

47.2

MomentumView details →

1D Return

−3.81%

YTD Return

−31.54%

SummaryUpdated Jun 1, 2026

Tiziana Life Sciences Ltd (NASDAQ:TLSA) is a biotechnology company founded in 1998 and headquartered in London, United Kingdom. The company went public on November 20, 2018, and focuses on discovering and developing therapeutic molecules to treat human diseases in oncology and immunology. As a clinical-stage biotechnology firm, Tiziana operates without generating revenue from product sales, instead relying on research and development activities to advance its pipeline of experimental treatments through various stages of clinical trials.

Ask drillr about Tiziana Life Sciences Ltd. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−5.4x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

−46.8x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

916.85%

ROA (TTM)

−216.00%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

−81.10%

FCF YoY

−60.71%

Revenue CAGR 3Y

—

EPS CAGR 3Y

−45.45%

EBITDA YoY

−64.61%

MomentumView details →

1D Return

−3.81%

YTD Return

−31.54%

1Y Return

−47.96%

RSI (14)

47.2

vs 50D SMA

−1.04%

vs 200D SMA

−17.61%

Capital & dividendView details →

Debt/Equity

−0.34x

Current Ratio

0.69x

Quick Ratio

0.69x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.08

EPS Surprise

−2.18%

Beats (12Q)

1/12

Next Q EPS Est

−$0.10

Avg Surprise (4Q)

−89.24%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−38.03M

Op. CF (TTM)

−21.74M

Next earningsMar 3, 2027 →

Latest newsMore news →

Tiziana Life Sciences Ltd announced that the last patient began dosing in its Phase 2 trial of intranasal foralumab for early/mild Alzheimer's disease.3d ago

Tiziana Life Sciences dosed the first three participants with intranasal foralumab in a Phase 2a trial in people with amyotrophic lateral sclerosis (ALS).21d ago

Similar companies

Acumen Pharmaceuticals, Inc.ABOS AN2 Therapeutics, Inc.ANTX Avidity Biosciences, Inc.RNA Voyager Therapeutics, Inc.VYGR Korro Bio, Inc.KRRO Nkarta, Inc.NKTX Find similar companies →

Latest newsMore news →

Tiziana Life Sciences Ltd announced that the last patient began dosing in its Phase 2 trial of intranasal foralumab for early/mild Alzheimer's disease.3d ago Tiziana Life Sciences dosed the first three participants with intranasal foralumab in a Phase 2a trial in people with amyotrophic lateral sclerosis (ALS).21d ago KAIMRC announced research collaborations with Olink in proteomics, Tiziana Life Sciences in immunomodulation and neuroimmunology, and Japan's Chiyoda Corporation on plant-based peptide production for cancer treatment.27d ago